8-K: McKesson Reports Strong FY26 Results, Guides FY27

McKesson Corporation announced robust fourth quarter and full fiscal year 2026 results, exceeding long-term growth targets, and provided positive guidance for fiscal year 2027.

Summary

• McKesson Corporation reported strong financial results for the fourth quarter and full fiscal year ended March 31, 2026.
• Consolidated revenues for the fourth quarter increased by 6% to $96.3 billion, and for the full year, revenues grew 12% to $403.4 billion.
• Earnings per diluted share (EPS) for the fourth quarter were $13.71, a 37% increase year-over-year, and full-year EPS was $38.38, a 49% increase.
• Adjusted Earnings per Diluted Share (Adjusted EPS) saw significant growth, increasing 16% to $11.69 in the fourth quarter and 18% to $39.11 for the full year, exceeding long-range growth targets.
• The company generated $6.2 billion in cash flow from operations and $5.4 billion in Free Cash Flow for the full fiscal year.
• McKesson reaffirmed its long-term Adjusted EPS growth target of 13% to 16% and provided fiscal year 2027 Adjusted EPS guidance of $43.80 to $44.60, representing 12% to 14% growth.
• The company announced a $5.0 billion increase to its share repurchase program, bringing the total authorization to $7.7 billion, and completed $2.7 billion in share repurchases in the fourth quarter.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive report, with the company exceeding its own growth targets and providing robust guidance for the upcoming fiscal year, alongside significant capital returns to shareholders.

Positives

• Consolidated revenues increased 6% to $96.3 billion in Q4 FY26 and 12% to $403.4 billion for the full year FY26.
• Adjusted Earnings per Diluted Share increased 16% to $11.69 in Q4 FY26 and 18% to $39.11 for the full year FY26, exceeding long-range growth targets.
• Full-year cash flow from operations was $6.2 billion and Free Cash Flow was $5.4 billion.
• Fiscal 2027 Adjusted EPS guidance of $43.80 to $44.60 indicates strong forecasted growth of 12% to 14%.
• Reaffirmed long-term Adjusted EPS growth target of 13% to 16%.
• Share repurchase program increased by $5.0 billion to a total authorization of $7.7 billion.
• Significant growth in the Oncology & Multispecialty segment with revenues up 35% in Q4 and 31% for the full year.
• Prescription Technology Solutions segment saw revenue growth of 12% in Q4 and 11% for the full year.

Negatives

• Medical-Surgical Solutions segment Adjusted Segment Operating Profit decreased by 5% in the fourth quarter.
• The company does not forecast GAAP earnings per diluted share due to the inability to provide a quantitative reconciliation of forward-looking Non-GAAP measures to GAAP without unreasonable effort.
• The planned separation of the Medical-Surgical Solutions business is subject to regulatory approvals and customary closing conditions.

Risks

• The planned separation of the Medical-Surgical Solutions segment may not be completed on the contemplated terms or timeline, or at all.
• Potential for costly and disruptive legal disputes and settlements, including regarding the distribution of controlled substances.
• Risk of losses not covered by insurance or indemnification.
• Subject to frequently changing, extensive, complex, and challenging healthcare and other laws and policies.
• Potential for cybersecurity incidents that could compromise technology systems or result in material data breaches.
• Risk of significant problems with information systems or networks.
• The adoption and use of artificial intelligence in business operations exposes the company to risks and uncertainties.
• Potential for unsuccessful achievement of strategic growth objectives or cost optimization initiatives.

Future Outlook

McKesson is establishing fiscal year 2027 Adjusted Earnings per Diluted Share guidance in the range of $43.80 to $44.60, indicating an expected growth of 12% to 14% compared to the prior year. The company is reaffirming its long-term Adjusted Earnings per Diluted Share growth target of 13% to 16%.

Management Comments

• "McKesson's fourth quarter results reflect the strength of our diversified portfolio and disciplined execution against our strategic priorities."
• "Our Fiscal 2026 performance, headlined by 12% revenue growth and 18% adjusted EPS growth, exceeded our long-range growth targets and demonstrates our ability to consistently deliver growth and operating leverage across the enterprise."
• "Looking ahead to fiscal 2027, we are well-positioned to build upon this momentum. We remain committed to executing with discipline across the portfolio, investing in high-growth and high-margin areas in Oncology and Biopharma Services."
• "By combining our operating execution with a more focused and optimized portfolio, we will continue to deliver sustainable growth and create long-term value for our shareholders."

Industry Context

StockSavvy.ai notes that McKesson's strong performance, particularly in its Oncology & Biopharma Services segments, aligns with broader industry trends of increasing demand for specialized healthcare solutions and integrated support services. The company's strategic divestitures and focus on high-growth areas reflect a common strategy among large healthcare distributors to streamline operations and enhance profitability in a competitive landscape.

Comparison to Industry Standards

• McKesson's full-year Adjusted EPS growth of 18% for FY26 significantly outpaces the average growth rates seen in the broader healthcare distribution sector, which typically hovers in the mid-to-high single digits.
• The company's reaffirmed long-term Adjusted EPS growth target of 13%-16% is at the higher end of industry benchmarks, suggesting confidence in its specialized service offerings and market position.
• Competitors like Cardinal Health and AmerisourceBergen (now Cencora) have also reported growth, but McKesson's reported growth in specialized areas like Oncology & Multispecialty (31% full-year revenue growth) often exceeds the more commoditized pharmaceutical distribution segments where competitors may have a larger proportional revenue base.

Management Changes

Legal Proceedings

• Potential for costly and disruptive legal disputes and settlements, including regarding the distribution of controlled substances such as opioids.

Stakeholder Impact

• Shareholders: Benefit from increased share repurchase authorization ($7.7 billion total) and strong financial performance, indicating potential for increased shareholder value.
• Employees: Continued focus on operational excellence and investment in high-growth areas may lead to job security and growth opportunities.
• Customers: Continued growth in specialized services like Oncology & Biopharma Services may lead to enhanced support and access to critical treatments.
• Suppliers: Strong revenue growth and operational efficiency may indicate stable demand and reliable payment for suppliers.

Next Steps

• Continue to optimize the portfolio through the divestiture of Europe and the planned separation of the Medical-Surgical business.
• Invest in high-growth and high-margin areas in Oncology and Biopharma Services.
• Participate in the BofA Securities 2026 Healthcare Conference on May 12, 2026.
• Continue to deliver sustainable growth and create long-term value for shareholders.

Key Dates

Recommendation

The company demonstrated strong financial performance exceeding its own targets, provided robust guidance for the next fiscal year, and significantly increased its share repurchase authorization. The strategic focus on high-growth specialized areas like Oncology and Biopharma Services, coupled with operational discipline, positions McKesson for continued value creation, making it an attractive investment.

Keywords

McKesson Corporation, Healthcare Services, Pharmaceutical Distribution, Oncology, Biopharma Services, Financial Results, Earnings Per Share, Share Repurchase